Aytu BioPharma (AYTU)
(Delayed Data from NSDQ)
$2.36 USD
-0.15 (-5.98%)
Updated Oct 10, 2025 04:00 PM ET
After-Market: $2.36 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
D Value A Growth F Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AYTU 2.36 -0.15(-5.98%)
Will AYTU be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for AYTU based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AYTU
Agilent Technologies (A) Surpasses Q3 Earnings and Revenue Estimates
AYTU: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for AYTU
Aytu BioPharma to Present at Upcoming October 2025 Conferences
The technical outlook for AYTU is unchanged after it rises 5.91% on October 9
AYTU rises 0.42% on October 8, leaving the technical picture intact
AYTU Crossed Above 50 Day Moving Average on October 7
Aytu BioPharma management to meet with Lake Street